A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone
(Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®;
now marketed as oxazepam (generic) only).
This is a Phase 2 study in approximately 80 adult subjects with moderate-to-severe Cocaine
Use Disorder (CUD).